Jazz Pharmaceuticals (JAZZ) free cash flow
Jazz Pharmaceuticals (JAZZ) generated free cash flow of $1.15B in fiscal 2025 (the year ended December 31, 2025). That is 15.0% lower than the $1.35B of fiscal 2024. Figures as of 18 Nov 2026, 12:01 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Free cash flow, fiscal 2025
- $1.15B
- Change on fiscal 2024
- −15.0%
- Growth, 5 years
- +5.3% a year
- Growth, 10 years
- +8.7% a year
- Highest on record
- $1.35Bfiscal 2024
- Lowest on record
- -$15.93Mfiscal 2009
- Fiscal years on record
- 172009–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Jazz Pharmaceuticals free cash flow, in more detail
Over the five fiscal years to 2025 free cash flow grew at a compound 5.3% a year; over ten years the rate was 8.7% a year. Across the 17 fiscal years on record (2009–2025), the highest was $1.35B in fiscal 2024 and the lowest -$15.93M in fiscal 2009.
Free cash flow by fiscal year
Jazz Pharmaceuticals free cash flow, year by year
| Fiscal year | Free cash flow | Change | Year ended |
|---|---|---|---|
| 2025 | $1.15B | 15.0% down | |
| 2024 | $1.35B | 28.5% up | |
| 2023 | $1.05B | 35.6% up | |
| 2022 | $773.78M | 3.1% up | |
| 2021 | $750.87M | 15.1% down | |
| 2020 | $884.64M | 20.2% up | |
| 2019 | $736.27M | 5.4% down | |
| 2018 | $778.53M | 17.2% up | |
| 2017 | $664.14M | 14.0% up | |
| 2016 | $582.70M | 17.5% up | |
| 2015 | $495.99M | 33.6% up | |
| 2014 | $371.26M | 33.3% up | |
| 2013 | $278.46M | 14.2% up | |
| 2012 | $243.78M | 62.2% up | |
| 2011 | $150.32M | 158.6% up | |
| 2010 | $58.14M | — | |
| 2009 | -$15.93M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.
How to read it
It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.
Free cash flow at health care companies of similar size
| Company | Free cash flow | Fiscal year |
|---|---|---|
| Ascendis Pharma ASND | €45.41M | 2025 |
| ICON ICLR | $861.99M | 2025 |
| Jazz Pharmaceuticals JAZZ | $1.15B | 2025 |
| Solventum SOLV | -$10.00M | 2025 |
| BridgeBio Pharma BBIO | -$455.50M | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Jazz Pharmaceuticals, figure by figure
- Jazz Pharmaceuticals market cap
- Jazz Pharmaceuticals revenue
- Jazz Pharmaceuticals earnings
- Jazz Pharmaceuticals earnings per share (EPS)
- Jazz Pharmaceuticals P/E ratio
- Jazz Pharmaceuticals P/S ratio
- Jazz Pharmaceuticals P/B ratio
- Jazz Pharmaceuticals operating margin
- Jazz Pharmaceuticals dividend
- Jazz Pharmaceuticals shares outstanding
- Jazz Pharmaceuticals total debt
- Jazz Pharmaceuticals cash on hand
- Jazz Pharmaceuticals total assets
- Jazz Pharmaceuticals return on equity (ROE)
- Jazz Pharmaceuticals return on invested capital (ROIC)
Jazz Pharmaceuticals (JAZZ) overview: price, valuation and scorecardAll health care companies by market value
Jazz Pharmaceuticals free cash flow: questions and answers
What is Jazz Pharmaceuticals's free cash flow?
Jazz Pharmaceuticals (JAZZ) generated free cash flow of $1.15B in fiscal 2025 (the year ended December 31, 2025). That is 15.0% lower than the $1.35B of fiscal 2024.
What is the growth rate of Jazz Pharmaceuticals's free cash flow?
Over the five fiscal years to 2025 free cash flow grew at a compound 5.3% a year; over ten years the rate was 8.7% a year.
What are the highest and lowest free cash flow figures on record for Jazz Pharmaceuticals?
Across the 17 fiscal years on record (2009–2025), the highest was $1.35B in fiscal 2024 and the lowest -$15.93M in fiscal 2009.
How is Jazz Pharmaceuticals's free cash flow calculated?
Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For Jazz Pharmaceuticals it is on record here for 17 fiscal years, 2009 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: free cash flow
All stocks guides →- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
- How a DCF valuation works, and why inputs swing it
A discounted cash flow (DCF) valuation estimates what a business is worth today by forecasting the cash it will produce and discounting each year's cash back at a required rate of return. Because most of the value lies far in the future, a one-point change in growth or discount rate can move the answer by a quarter.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Jazz Pharmaceuticals (JAZZ) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/JAZZ/free-cash-flow
Underlying data: the company's filings with the SEC and Yahoo Finance.